After a couple years of early retirement from his 32-year career as a biotechnology engineer in Flow Immunocytometry research, John was diagnosed with aggressive prostate cancer. He was told he had between six months and two years to live, and soon began chemotherapy with limited response.
His oncologist sent John’s tumor for New Era Genomic Sequencing and found that it had a high mutational burden, which made him a good candidate for immunotherapy. In August 2016, he began receiving infusions of pembrolizumab (Keytruda®) and within three months the tumor showed signs of regression. Four years after beginning immunotherapy he has a complete and durable clinical remission with no evidence of disease.
Today, John is a patient advocate, focusing on engaging and educating the public on the importance of genomic sequencing.
In 2014, I had urinary symptoms. I saw a doctor for diagnostic testing to confirm disease: prostate cancer.
I decided to do immunotherapy when all hope from conventional treatment failed. I am very familiar with immunotherapy from my background as a biotechnology engineer. After genomic sequencing, immunotherapy was my best option going forward.
I didn't have side effects other than adrenal insufficiency, which I controlled with low dose of the steroid prednisone.
There is simply no comparison between the one and a half years of chemotherapy and immunotherapy I am currently receiving. During immunotherapy, I don’t have the sickness, fatigue, loss of appetite, or general non well-being that I experienced with chemotherapy.
I have tolerated 48 infusions thus far with the goal of 50 before being weaned-off by the end of 2020. I haven’t experienced any limitations on my active lifestyle.
This experience changed me as a person. My compassion and care for others has increased, along with my knowledge of the disease.
A clinical trial could be your lifesaver when all else fails. Speak to your providers about genomic sequencing to determine if you are a candidate.
Provide guidance and encouragement to others going through their journey with cancer immunotherapy treatment.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
Rare and ultra-rare cancers affect around 20,000 people in the United States alone, according to Foundation Medicine, Inc. Immunotherapy research in some of the more common cancers and the identification of biomarkers that can predict patient responses is opening this new approach to cancer treatment up to patients whose cancers currently receive little direct attention.
Cancer is not “one-size-fits-all” and neither are its treatments, especially when it comes to immunotherapy. Learn how CRI is helping more people overcome cancer.